DexCom sees FY25 revenue $4.6B, consensus $4.6B

For 2025, Dexcom (DXCM) currently anticipates total revenue of $4.6B, representing expected growth of approximately 14% over 2024. This outlook considers sensor volume growth driven by increasing CGM access and awareness for people with diabetes, the continued rollout of Stelo, further international expansion, and overall market dynamics. In addition, Dexcom currently estimates 2025 Non-GAAP Gross Profit Margin and Non-GAAP Operating Margin to be at the following levels: Non-GAAP Gross Profit Margin of approximately 64 – 65%: Non-GAAP Operating Margin of approximately 21%